AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18808630 — intervention group
Group type: COMPARATOR
Intervention: Control group (worn headphones without music)
Number of subjects: 44
Study 16104916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises with biofeedback and lifestyle changes
Number of subjects: 55
Study 16104916 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes only (control group)
Number of subjects: 55
Study 16104916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (after crossover from control)
Number of subjects: 55
Study 11921321 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic agents
Number of subjects: 0
Study 11921321 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for cost-effectiveness analysis
Number of subjects: 0
Study 11921321 — intervention group
Group type: EXPERIMENTAL
Intervention: One-tailed t test
Number of subjects: 0
Study 11921321 — intervention group
Group type: EXPERIMENTAL
Intervention: CMCB confidence interval
Number of subjects: 0
Study 11921321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fieller's theorem
Number of subjects: 0
Study 10037349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical fluorescence measurement in women with no history of cervical dysplasia
Number of subjects: 54
Study 10037349 — intervention group
Group type: COMPARATOR
Intervention: Previously reported diagnostic algorithms
Number of subjects: 54
Study 7745513 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 232
Study 7745513 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 232
Study 1646182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FXT) 60 mg daily (n = 11)
Number of subjects: 23
Study 1646182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) (n = 12)
Number of subjects: 23
Study 1646182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FXT)
Number of subjects: 23
Study 1646182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study 6941408 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg domperidone i.v.
Number of subjects: 10
Study 6941408 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no treatment not specified)
Number of subjects: 10
Study 31085108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing chemotherapy
Number of subjects: 139
Study 31085108 — intervention group
Group type: COMPARATOR
Intervention: Non-bevacizumab-based regimens
Number of subjects: 139
Study 28249030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed low dose ESA (4000 IU epoetin alfa equivalent weekly)
Number of subjects: 656
Study 28249030 — intervention group
Group type: COMPARATOR
Intervention: Fixed high dose ESA (18,000 IU epoetin alfa equivalent weekly)
Number of subjects: 656
Study 26934484 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height <147.5 cm
Number of subjects: 1054
Study 26934484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with no education
Number of subjects: 1054
Study 26934484 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceived in the pre-monsoon season
Number of subjects: 1054
Study 26934484 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1054
Study 26934484 — intervention group
Group type: COMPARATOR
Intervention: Height-for-age Z-scores (HAZ)
Number of subjects: 1054
Study 26934484 — intervention group
Group type: COMPARATOR
Intervention: Height-for-age difference in cm (HAD)
Number of subjects: 1054
Study 25161160 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus voglibose
Number of subjects: 22
Study 25161160 — intervention group
Group type: COMPARATOR
Intervention: Metformin only
Number of subjects: 22
Study 22935052 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg orally three times daily for 28 days
Number of subjects: 560
Study 22935052 — intervention group
Group type: COMPARATOR
Intervention: Placebo 10 mg orally three times daily for 14 days followed by Domperidone 10 mg orally three times daily for 14 days
Number of subjects: 560
Study 19834698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic drugs (e.g., levodopa)
Number of subjects: 0
Study 19834698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondopaminergic drugs (e.g., folic acid, methylphenidate, aplindore, levetiracetam, Neu 120)
Number of subjects: 0
Study 19834698 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed drugs with known mode of action
Number of subjects: 0
Study 19834698 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale, well-designed, multicenter trials
Number of subjects: 0
Study 17482465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen or Raloxifene
Number of subjects: 33
Study 15764958 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of Abacavir (ABC) administered once daily
Number of subjects: 770
Study 15764958 — intervention group
Group type: COMPARATOR
Intervention: 300 mg of Abacavir (ABC) administered twice daily
Number of subjects: 770
Study 12169964 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with mitomycin C (DSMMC group)
Number of subjects: 90
Study 12169964 — intervention group
Group type: COMPARATOR
Intervention: Deep sclerectomy without mitomycin C (DS group)
Number of subjects: 90
Study 10641957 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 10641957 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 10641957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem (INTERCEPT trial)
Number of subjects: 0
Study 1453405 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic saline amnioinfusion
Number of subjects: 53
Study 3902784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary management involving a doctor, physiotherapist, psychologist, and social worker
Number of subjects: 0
Study 3902784 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30389429 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing enzymes and proteins
Number of subjects: 0
Study 29596217 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 financial incentive for HIV testing
Number of subjects: 60
Study 29596217 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 financial incentive for HIV testing
Number of subjects: 60
Study 29596217 — intervention group
Group type: EXPERIMENTAL
Intervention: $15 financial incentive for HIV testing
Number of subjects: 60
Study 29596217 — intervention group
Group type: COMPARATOR
Intervention: No financial incentives
Number of subjects: 60
Study 26932230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 100
Study 26932230 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study 26178160 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg orally each night for 1 week
Number of subjects: 72
Study 26178160 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally each night for 1 week
Number of subjects: 72
Study 24093737 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic relaxation techniques (reading relaxing sentences during recovery)
Number of subjects: 124
Study 24093737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation techniques)
Number of subjects: 124
Study 24093737 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic relaxation techniques
Number of subjects: 124
Study 20679619 — intervention group
Group type: EXPERIMENTAL
Intervention: EOC + P (epirubicin 50 mg/m(2), oxaliplatin 130 mg/m(2), capecitabine 1,000 mg/m(2)/d + P 9 mg/kg every 3 weeks)
Number of subjects: 29
Study 20679619 — intervention group
Group type: EXPERIMENTAL
Intervention: EOC + P (DL-1)
Number of subjects: 29
Study 20679619 — intervention group
Group type: EXPERIMENTAL
Intervention: EOC + P (DL-2)
Number of subjects: 29
Study 20679619 — intervention group
Group type: COMPARATOR
Intervention: EOC (standard dose)
Number of subjects: 29
Study 18215666 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraosseous injection of 1.4 mL of 2% lidocaine with epinephrine
Number of subjects: 55
Study 18215666 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intraosseous injection given 30 minutes after the primary injection
Number of subjects: 55
Study 18215666 — intervention group
Group type: COMPARATOR
Intervention: Mock injection at 30 minutes
Number of subjects: 55
Study 16618470 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Physical Treatment (APT, n = 52)
Number of subjects: 211
Study 16618470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT, n = 55)
Number of subjects: 211
Study 16618470 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Treatment (CT, n = 55)
Number of subjects: 211
Study 16618470 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL, n = 49)
Number of subjects: 211
Study 14725386 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush plus plaque disclosing tablet (SIGNAL Integral)
Number of subjects: 21
Study 14725386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste and saliva test strips
Number of subjects: 21
Study 14725386 — intervention group
Group type: COMPARATOR
Intervention: Marketed toothbrush (Oral B Cross Action)
Number of subjects: 21
Study 14725386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no saliva test strips)
Number of subjects: 21
Study 10758969 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1216
Study 10758969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1216
Study 9227926 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection or ablation of endometriosis
Number of subjects: 341
Study 9227926 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic laparoscopy only
Number of subjects: 341
Study 8219659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg/day) after placebo treatment
Number of subjects: 18
Study 8219659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3305057 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), peroral dose 200 mg three times daily
Number of subjects: 25
Study 3305057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31945066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 822
Study 31945066 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (RAL)
Number of subjects: 822
Study 29249276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive rifampicin (600 mg or 900 mg per day for 2 weeks)
Number of subjects: 758
Study 29249276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 758
Study 29249276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive rifampicin
Number of subjects: 758
Study 27350131 — intervention group
Group type: EXPERIMENTAL
Intervention: Step It Up intervention (delivered during NHS Health Check)
Number of subjects: 1140
Study 27350131 — intervention group
Group type: COMPARATOR
Intervention: NHS Health Check only (control arm)
Number of subjects: 1140
Study 24814601 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate weight-bearing
Number of subjects: 0
Study 24814601 — intervention group
Group type: COMPARATOR
Intervention: Affected limb
Number of subjects: 0
Study 24814601 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ultrasound measurement
Number of subjects: 0
Study 22820788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, 400 mg once daily for 48 weeks
Number of subjects: 83
Study 22820788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21105284 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 8
Study 21105284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine (10 mg)
Number of subjects: 8
Study 21105284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18275682 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiological doses of PYY3-36
Number of subjects: 6
Study 15718036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu/Glu genotype in late onset AD (LOAD) patients
Number of subjects: 405
Study 15718036 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AD
Number of subjects: 405
Study 15718036 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LOAD
Number of subjects: 405
Study 15718036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu/Glu homozygous genotype
Number of subjects: 405
Study 15718036 — intervention group
Group type: EXPERIMENTAL
Intervention: AD patients
Number of subjects: 405
Study 15718036 — intervention group
Group type: EXPERIMENTAL
Intervention: LOAD patients
Number of subjects: 405
Study 15718036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu/Glu genotype
Number of subjects: 405
Study 12573274 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk models for death
Number of subjects: 15904
Study 12573274 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk models for death or myocardial infarction (MI)
Number of subjects: 15904
Study 12573274 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk models for death, MI, or severe recurrent ischaemia (SRI)
Number of subjects: 15904
Study 10529526 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF 1% F(‐) solution applied twice a year on the enamel surfaces of the first permanent molars for 5 years
Number of subjects: 284
Study 10529526 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution applied twice a year on the enamel surfaces of the first molars for 5 years
Number of subjects: 284
Study 10529526 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF 1% F(‐) solution in low-SMS subjects
Number of subjects: 284
Study 10529526 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution in low-SMS subjects
Number of subjects: 284
Study 10529526 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF 1% F(‐) solution in high-SMS subjects
Number of subjects: 284
Study 10529526 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution in high-SMS subjects
Number of subjects: 284
Study 8685949 — intervention group
Group type: COMPARATOR
Intervention: CMV immune globulin prophylaxis
Number of subjects: 141
Study 8685949 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV viremia
Number of subjects: 141
Study 8685949 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive fungal disease
Number of subjects: 141
Study 8685949 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal reoperation
Number of subjects: 141
Study 1522289 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish
Number of subjects: 31
Study 1522289 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel (daily application for one week)
Number of subjects: 31
Study 1522289 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 31
Study 1522289 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 31
Study 6443719 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous transhepatic biliary drainage
Number of subjects: 0
Study 6443719 — intervention group
Group type: COMPARATOR
Intervention: Preoperative external drainage
Number of subjects: 0
Study 6443719 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative internal drainage
Number of subjects: 0
Study 6443719 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical well-accepted drainage period of 2-4 weeks
Number of subjects: 0
Study 6443719 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous approach
Number of subjects: 0
Study 31371150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower frequency (28 kHz) phacoemulsification
Number of subjects: 160
Study 31371150 — intervention group
Group type: COMPARATOR
Intervention: Higher frequency (42 kHz) phacoemulsification
Number of subjects: 160
Study 29710060 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program plus standard care
Number of subjects: 50
Study 29710060 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 25881564 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injections (ABIs)
Number of subjects: 22
Study 25881564 — intervention group
Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 22
Study 25881564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ABI and saline groups
Number of subjects: 22
Study 24322378 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema therapy
Number of subjects: 323
Study 24322378 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 323
Study 24322378 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarification-oriented psychotherapy
Number of subjects: 323
Study 24322378 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 323
Study 24322378 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-cohort schema therapists
Number of subjects: 323
Study 24322378 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview-based measures
Number of subjects: 323
Study 24322378 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 323
Study 22064687 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site monitoring
Number of subjects: 104
Study 22064687 — intervention group
Group type: EXPERIMENTAL
Intervention: Central monitoring techniques
Number of subjects: 104
Study 22064687 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant folder review at site
Number of subjects: 104
Study 19161758 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (12 microg/kg bolus, followed by an infusion of 0.2 microg/kg/min)
Number of subjects: 60
Study 19161758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17763227 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U of botulinum toxin A (BTX‐A; Dysport)
Number of subjects: 31
Study 14975769 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus-irrelevant distracting conversation
Number of subjects: 27
Study 14975769 — intervention group
Group type: COMPARATOR
Intervention: Stimulus-relevant focused conversation
Number of subjects: 27
Study 11695208 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 63
Study 11695208 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice
Number of subjects: 63
Study 9474184 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month course of 300 mg neoadjuvant cyproterone acetate daily
Number of subjects: 213
Study 9474184 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy alone
Number of subjects: 213
Study 7754260 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2371437 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 1 g twice daily with probenecid
Number of subjects: 6
Study 2371437 — intervention group
Group type: COMPARATOR
Intervention: High dose amoxycillin 3 g twice daily
Number of subjects: 6
Study 782773 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg dextroamphetamine sulfate and 50 mug/kg THC from marihuana cigarette
Number of subjects: 0
Study 782773 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg dextroamphetamine sulfate and 25 mug/kg THC from marihuana cigarette
Number of subjects: 0
Study 782773 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dextroamphetamine and marihuana
Number of subjects: 0
Study 31315685 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages with information on job openings plus information on HIV prevention, business educational sessions, a mentored apprenticeship, and a start‐up grant, and business and HIV prevention text messages based on principles from behavioral economics.
Number of subjects: 40
Study 31315685 — intervention group
Group type: COMPARATOR
Intervention: Text messages with information on job openings.
Number of subjects: 40
Study 27254132 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Autogenic Drainage (AAD)
Number of subjects: 103
Study 27254132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive Ventilation (IPV)
Number of subjects: 103
Study 27254132 — intervention group
Group type: COMPARATOR
Intervention: Bouncing (Control Group)
Number of subjects: 103
Study 25840525 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed 3/0 V‐Loc™180 suture
Number of subjects: 33
Study 25840525 — intervention group
Group type: COMPARATOR
Intervention: Smooth 3/0 Maxon™ sutures
Number of subjects: 33
Study 23216615 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg apixaban, twice daily
Number of subjects: 2482
Study 23216615 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg apixaban, twice daily
Number of subjects: 2482
Study 23216615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2482
Study 21216852 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion during normoglycemia
Number of subjects: 102
Study 18359423 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics measured at baseline and day 3
Number of subjects: 563
Study 18359423 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 563
Study 18359423 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of ventilation before enrollment
Number of subjects: 563
Study 18359423 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of neurologic disease at admission
Number of subjects: 563
Study 18359423 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of the Pao2/Fio2 ratio to improve by day 3
Number of subjects: 563
Study 18359423 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of fever
Number of subjects: 563
Study 16919577 — intervention group
Group type: EXPERIMENTAL
Intervention: Community volunteers
Number of subjects: 848
Study 16919577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac patients with LVEF >= 0.50
Number of subjects: 848
Study 16919577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac patients with LVEF < 0.50
Number of subjects: 848